EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 449 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... February 16, 2022 Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs January 27, 2022 Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... February 24, 2025 GreaterGood Charities Provides Supplies and Support to People and Pets After... December 17, 2021 Load more HOT NEWS The Timing for the Age of which Natural Menopause Occurs Philanthropist Simon Collins: “I realised I could make a difference by... Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical...
